| DC60083 |
ZINC77292789(Fmoc-Thr(galnac(Ac)3-alpha-D)-OH)
Featured
|
ZINC77292789 is a reagent for making synthetic MUC1 Glycopeptide Bearing βGalNAc-Thr as a Tn Antigen Isomer Induces the Production of Antibodies against Tumor Cells. ZINC77292789 was a starting material to make trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
|
|
| DC60084 |
OVN73571
Featured
|
OVN73571, also known as Fmoc-Ser[GalNAc(Ac)3-α-D]-OH, is a useful chemical intermediate for synthesis of Tn/T Antigen MUC1 Glycopeptide BSA Conjugates, which can use used as Vaccines. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS.
|
|
| DC60085 |
MYF-01-37
Featured
|
MYF-01-37 is a novel covalent inhibitor of TEAD targeting Cys380 when incubated with the TEAD2 protein.
|
|
| DC60086 |
Lasmiditan HCl
Featured
|
Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. Lasmiditan showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo.
|
|
| DC60087 |
Boc-Gly-Gly-Phe-Gly-OH
Featured
|
Boc-Gly-Gly-Phe-Gly-OH is a protease cleavable linker used for the antibody-drug conjugate (ADC).
|
|
| DC60088 |
SIN44126
Featured
|
SIN44126 is a IRAK4 inhibitor, which was first described in patent WO 2015104688. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature .
|
|
| DC60089 |
GUN30820
Featured
|
GUN30820, also known as Brr2 inhibitor C9 or Brr2 Inhibitor 9, is an allosteric inhibitor of the spliceosomal RNA helicase Brr2. Brr2 is implicated in autosomal-dominant retinitis pigmentosa a group of progressive retinal degenerative disorders. GUN30820 was first described in Journal of Medicinal Chemistry (2017), 60(13), 5759-5771. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature
|
|
| DC60090 |
WWL 154
Featured
|
WWL-154 is a serine hydrolase inhibitor. Serine hydrolases (SHs) are-one of the largest and most diverse enzyme classes in mammals. They play fundamental roles in virtually all physiol. processes and are targeted by drugs to treat diseases such as diabetes, obesity, and neurodegenerative disorders.
|
|
| DC60091 |
KUN56321
Featured
|
KUN56321 is a luminescent agent. The application of KUN56321 comprises: coating the film of KUN56321 onto hole transport layer or electron transport layer of ITO glass by vacuum evapn., coating the hole transport layer or electron transport layer onto the film by evapn., prepg. metal electrode by evapn. KUN56321 showed the capability to improve light emitting efficiency and reducing drive voltage in org. light-emitting device and display device. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature .
|
|
| DC57040 |
EUK-134
Featured
|
EUK-134 is an antioxidant compound with superoxide dismutase and catalase activity for oxidative species such as peroxynitrite, superoxide, and hydrogen peroxide. |
|
| DC57041 |
N-Me-L-Ala-maytansinol
Featured
|
N-Me-L-Ala-maytansinol is a maytansine derivative. .N-Me-L-Ala-maytansinol can be used for synthesis of antibody-drug conjugate (ADC). |
|
| DC57042 |
DEOXYNIVALENOL
Featured
|
Deoxynivalenol, a mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors[1]. |
|
| DC57046 |
ATX-126(ATX-0126, lipid 10p)
Featured
|
ATX-126(ATX-0126, 10p) is an ionizable cationic lipid (pKa = 6.38).It has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA. Intravenous administration of LNPs containing ATX-126(ATX-0126, 10p) and encapsulating Factor VII siRNA decrease Factor VII blood levels in mice. |
|
| DC57100 |
Acuitas Lipid A9
Featured
|
Lipid A9 is an ionizable cationic lipid (pKa = 6.27) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and siRNA in vivo. LNPs containing lipid A9 and encapsulating non-stimulatory siRNA increase plasma levels of chemokine (C-C motif) ligand 2 (CCL2), indicating activation of the innate immune response, and decrease body weight in mice. |
|
| DC60092 |
DWN63831
Featured
|
DWN63831 is a lysyl oxidase inhbitor. DWN63831 may be useful in treatment of a variety of disorders, e.g., fibrosis, cancer and angiogenesis in human subjects as well as in pets and livestock. DWN63831 was first reported in patent WO 2020024017.
|
|
| DC60093 |
AAN06119
Featured
|
AAN06119 is a chemical reagent. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature.
|
|
| DC60094 |
Val-Lys(Boc)-PAB
Featured
|
Val-Lys(Boc)-PAB is a ADC linker. Val-Lys(Boc)-PAB was used to prepare camptothecin peptide conjugates as antitumor agents (WO 2019195665). It was used as a non-linear self-immolative linker for reducing hydrophobicity of antibody-drug conjugates for cancer therapy (WO 2018069375).
|
|
| DC60095 |
NV-5138
Featured
|
NV-5138 is an orally and centrally active small-molecule drug for the treatment of major depressive disorder (MDD). It directly and selectively activates the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway by binding to and modulating sestrin2, a leucine amino acid sensor and upstream regulatory pathway. The mTORC1 pathway is the same signaling pathway that the NMDA receptor antagonist ketamine activates in the medial prefrontal cortex (mPFC) to mediate its rapid-acting antidepressant effects. A single oral dose of NV-5138 has been found to increase mTORC1 signaling and produce synaptogenesis in the mPFC and to induce rapid antidepressant effects in multiple animal models of depression.
|
|
| DC60096 |
FBN33428
Featured
|
FBN33428, also known as Fmoc-Phe-Lys(Boc)-PAB; is a Hydrolyzable linker for making ADC conjugate. FBN33428 is useful for mkaing hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells. FBN33428 was first reported in WO 9813059. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digits of its CAS number or its molecule weight if its CAS number is not available.
|
|
| DC60097 |
TKN87180
Featured
|
TKN87180 is a Hydrolyzable linker for making ADC conjugate. TKN87180 was first reported in Bioorganic & Medicinal Chemistry Letters (2004), 14(16), 4323-4327. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digits of its CAS number or its molecule weight if its CAS number is not available.
|
|
| DC60098 |
ZYN57939
Featured
|
ZYN57939 is RNA polymerase I inhibitor for treating RNA polymerase I-mediated diseases. ZYN57939 was first reported in CN 104177379 A 20141203 (2014). ZYN57939 showed inhibitory activity with IC50 of 0.855 μM against human HT-29 cancer cell lines. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digits of its CAS number or its molecule weight if its CAS number is not available (see MedKoo Chemical Nomenclature.
|
|
| DC60099 |
JUN04542
Featured
|
JUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase-dependent disorders. JUN04542 was first reported in WO 2019148044 (2019). This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digits of its CAS number or its molecule weight if its CAS number is not available .
|
|
| DC60100 |
Diosgenin palmitate
Featured
|
Diosgenin palmitate, also known as Diosgenin hexadecanoate, is the hexadecanoic ester of Diosgenin. Diosgenin, a phytosteroid sapogenin, is the product of hydrolysis by acids, strong bases, or enzymes of saponins, extracted from the tubers of Dioscorea wild yam, such as the Kokoro. The sugar-free (aglycone) product of such hydrolysis, diosgenin is used for the commercial synthesis of cortisone, pregnenolone, progesterone, and other steroid products.
|
|
| DC60101 |
AH10639 phosphate
Featured
|
AH10639 is a novel inhibitor of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
|
|
| DC60102 |
MUN57694
Featured
|
MUN57694 is 26S proteasome inhibitor. MUN57694 was reported in WO 2006128196. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digits of its CAS number or its molecule weight if its CAS number is not available
|
|
| DC60103 |
PSMA11
Featured
|
PSMA-11 is a critical tool in nuclear medicine, enabling the synthesis of Ga-68-PSMA-11 for PET imaging of PSMA-expressing tumors. Its high specificity for PSMA, combined with the favorable properties of Ga-68, makes it a valuable diagnostic agent in the management of prostate cancer and potentially other malignancies. |
|
| DC60104 |
Episilvestrol
Featured
|
Episilvestrol, a derivative of silvestrol, is isolated from the fruits and twigs of Aglaia silvestris, Episilvestrol exhibited potent in vitro cytotoxic activity
|
|
| DC60105 |
SEN 12333
Featured
|
SEN-12333, also known as WAY-31753, is is a selective agonist of the alpha(7) nAChR (EC50 = 1.6 μM, Ki = 260 nM at rat α7 nAChRs). SEN-12333 displayed excellent in vitro and in vivo profiles, excellent brain penetration and oral bioavailability, and demonstrates in vivo efficacy in multiple behavioural cognition models.
|
|
| DC60106 |
MC-Ala-Ala-Asn(Trt)-PAB
Featured
|
MC-Ala-Ala-Asn(Trt)-PAB, is a hetero bifunctional cross-linker, useful in antibody drug conjugation (ADC). MC-Ala-Ala-Asn(Trt)-PAB is a fissionable linker which is specifically activated in a tumor microenvironment. XQN70430 was reported in patent WO 2016026458. |
|
| DC60107 |
MUN36378
Featured
|
MUN36378 is a FTO inhibitor for treatment of leukemia. This compound was first reported in patent WO 2018157842. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature.
|
|
